.DELTA.8- and .DELTA.9-prostaglandin derivatives, process for their
production and their pharmaceutical use
    4.
    发明授权
    .DELTA.8- and .DELTA.9-prostaglandin derivatives, process for their production and their pharmaceutical use 失效
    DELTA 8-和DELTA 9-前列腺素衍生物,其生产过程及其药物用途

    公开(公告)号:US5376683A

    公开(公告)日:1994-12-27

    申请号:US982111

    申请日:1992-11-25

    IPC分类号: C07C405/00 A61K31/557

    CPC分类号: C07C405/00

    摘要: The invention relates to .DELTA..sup.8 - and .DELTA..sup.9 -prostaglandin derivatives of formula I, ##STR1## in which means the radicals or , R.sup.1 means ##STR2## COOR.sup.4 or CONHR.sup.5, R.sup.2 and R.sup.3 respectively mean a hydrogen atom or a hydroxy group, and the OH group can be respectively in alpha- or beta- position,means a CH.sub.2 group, an O or S atom,W means hydrogen, --OR.sup.6, halogen, --CN--, --NO.sub.2, trifluoromethyl or COOR.sup.6, and if R.sup.4 means hydrogen, their salts with physiologically compatible bases, the alpha-, beta- or gamma- cyclodextrin clathrates, as well as the compounds of formula I encapsulated with liposomes, process for their production and their pharmaceutical use.

    摘要翻译: 本发明涉及式I的DELTA 8-和DELTA 9-前列腺素衍生物,其中R 1和R 3分别表示氢原子或羟基,R 1和R 3分别表示氢原子或羟基 基团,OH基团可以分别为α-或β-位,是指CH 2基团,O或S原子,W表示氢,-OR 6,卤素,-CN-,-NO 2,三氟甲基或COOR 6,如果 R4表示氢,它们与生理相容性碱的盐,α-,β-或γ-环糊精包合物,以及用脂质体包封的式I化合物,其制备方法及其药物用途。

    2-oxabicyclo(2,2,1)heptane derivatives and pharmaceutical
    5.
    发明授权
    2-oxabicyclo(2,2,1)heptane derivatives and pharmaceutical 失效
    2-OXABICYCLO(2,2,1)HEPTANE DERIVATIVES AND PHARMACEUTICAL

    公开(公告)号:US5235072A

    公开(公告)日:1993-08-10

    申请号:US679054

    申请日:1991-05-07

    摘要: The invention relates to 2-oxabicyclo[2.2.1]heptane derivatives of formula I ##STR1## as well as their enantiomers, in which, e.g., A means --(CH.sub.2).sub.n --, (E)-- or (Z)--CH.dbd.CH--, --C.tbd.C, --O-- or --S--,B means hydrogen, C.sub.1 -C.sub.10 alkyl, --OR.sup.2, halogen, --C.tbd.N, --N.sub.3, --COOR.sup.3,R.sup.1 means oxygen or a --CH.sub.2 group, ##STR2## Z means --(CH.sub.2).sub.p --, (E)--CH.dbd.CH--, --C.tbd.C--, W means a direct bond, a free or functionally modified hydroxymethylene group or a free or functionally modified ##STR3## in which the OH group can be respectively in alpha- or beta-position, D means a direct bond, a saturated alkylene group with 1-5 C atoms, a branched saturated or a straight-chain of branched unsaturated alkylene group with 2-5 C atoms,E means a direct bond, --C.tbd.C-- or --CH.dbd.CR.sup.7,R.sup.8 means hydrogen, C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 cycloalkyl, optionally substituted C.sub.6 -C.sub.12 aryl or a 5- or 6-member heterocyclic radical, andif R.sup.5 means hydrogen, their salts with physiologically compatible bases, as well as the alpha-, beta- or gamma-cyclodextrin clathrates, as well as the compounds of formula I encapsulated with liposomes, process for their production and the pharmaceutical agents containing these compounds.The compounds are thromboxane antagonists.

    摘要翻译: PCT No.PCT / DE89 / 00585 Sec。 371日期1991年5月7日 102(e)日期1991年5月7日PCT提交1989年9月7日PCT公布。 出版物WO90 / 02740 1990年3月22日。本发明涉及式I(I)的2-氧杂二环[2.2.1]庚烷衍生物及其对映异构体,其中例如A表示 - (CH 2)n - (E) - 或(Z)-CH = CH - , - C 3BOND C,-O-或-S-,B表示氢,C1-C10烷基,-OR2,卤素,-C3NN,-N3, COOR 3,R 1表示氧或-CH 2基,Z表示 - (CH 2)p - ,(E)-CH = CH-,-C 3BOND C-,W表示直接键,游离或官能改性的羟基亚甲基 基团或其中OH基团可以分别位于α或β位的游离或功能修饰的“IMAGE”,D表示直接键合,具有1-5个C原子的饱和亚烷基,支链饱和或直链, 具有2-5个C原子的支链不饱和亚烷基链,E表示直接键,-C 3 D或-CH = CR 7,R 8表示氢,C 1 -C 10烷基,C 3 -C 10环烷基,任选取代的C 6 -C 12芳基 或5或6元杂环基,如果R 5表示氢,则其与生理上相容的碱的盐,以及碱 ha-,β-或γ-环糊精包合物,以及用脂质体包封的式I化合物,其制备方法和含有这些化合物的药剂。 化合物是血栓素拮抗剂。